RheumaGen engineers curative therapeutics by precisely editing the human leukocyte antigen (HLA) genes that drive autoimmune disorders. Its platform is designed to produce one-time cell and gene therapies that block disease at the immune source without broad immunosuppression. The company has demonstrated progress in rheumatoid arthritis and is now expanding into celiac disease, aiming to generate preclinical proof of concept for that indication. RheumaGen partners with the ClinImmune Center for Clinical Immunology at the University of Colorado Anschutz Medical Campus for clinical development and manufacturing. Headquartered in Aurora, Colorado, the privately held firm recently secured Series A-1 financing to move its celiac program through early development. Although specific operating metrics such as revenue or patient data were not disclosed, the new capital underscores investor confidence in the company’s HLA gene-editing platform and experienced team. Management believes the approach could ultimately help millions of patients living with autoimmune disease.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2025